DiscoverThe Genetics PodcastEP 166: Developing targeted therapies for ALS with Eric Green from Trace Neuroscience, Maze Therapeutics, and Stanford University
EP 166: Developing targeted therapies for ALS with Eric Green from Trace Neuroscience, Maze Therapeutics, and Stanford University

EP 166: Developing targeted therapies for ALS with Eric Green from Trace Neuroscience, Maze Therapeutics, and Stanford University

Update: 2024-12-19
Share

Description

This week we’re joined by Eric Green, Founder and CEO of Trace Neuroscience, Co-Founder and Chief Scientific Officer at Maze Therapeutics, and Adjunct Clinical Assistant Professor at Stanford University School of Medicine. Eric and Patrick discuss Eric’s transition from cardiology to the world of entrepreneurship, the role of highly focused biotechs in creating precision therapies, and the development of high-impact gene therapies for people with amyotrophic lateral sclerosis (ALS).
Comments 
In Channel
EP 208: Gene therapy at a crossroads: Successes, concerns, and the path forward

EP 208: Gene therapy at a crossroads: Successes, concerns, and the path forward

2025-10-0942:58

EP 207: Decoding Parkinson’s genetics on a global scale with Andy Singleton and Sonya Dumanis of GP2 and ASAP

EP 207: Decoding Parkinson’s genetics on a global scale with Andy Singleton and Sonya Dumanis of GP2 and ASAP

2025-10-0212:59

EP 206: From caregiving to catalyzing FTD research with Wanda Smith of CureGRN

EP 206: From caregiving to catalyzing FTD research with Wanda Smith of CureGRN

2025-09-2507:12

EP 205: From father to biotech founder: Building hope for children with ultra-rare diseases with Terry Pirovolakis of Elpida Therapeutics

EP 205: From father to biotech founder: Building hope for children with ultra-rare diseases with Terry Pirovolakis of Elpida Therapeutics

2025-09-1843:46

EP 204: Bringing cardiovascular genetics and biobank discoveries into the clinic with Samuli Ripatti of the University of Helsinki

EP 204: Bringing cardiovascular genetics and biobank discoveries into the clinic with Samuli Ripatti of the University of Helsinki

2025-09-1106:15

EP 203: Building the tools behind modern genomics with Jonathan Marchini of Regeneron

EP 203: Building the tools behind modern genomics with Jonathan Marchini of Regeneron

2025-09-0438:20

EP 202: Biotech at the intersection of science and politics with Max Bronstein of Aviva Strategies

EP 202: Biotech at the intersection of science and politics with Max Bronstein of Aviva Strategies

2025-08-2845:46

EP 201: The gene therapy playbook: Successes, setbacks, and the path forward with Richard Wilson of Astellas

EP 201: The gene therapy playbook: Successes, setbacks, and the path forward with Richard Wilson of Astellas

2025-08-2147:28

EP 200: From predictions to breakthroughs in genetics and biotech

EP 200: From predictions to breakthroughs in genetics and biotech

2025-08-1434:40

EP 199: Functional genomics at scale: Using in vivo perturbations to study genetic risk variants in the brain with Xin Jin of Scripps Research Institute

EP 199: Functional genomics at scale: Using in vivo perturbations to study genetic risk variants in the brain with Xin Jin of Scripps Research Institute

2025-08-0736:31

EP 198: Reimagining clotting disorders: Patient voices and “unreasonable” leadership with Benny Sorenson of Hemab Therapeutics

EP 198: Reimagining clotting disorders: Patient voices and “unreasonable” leadership with Benny Sorenson of Hemab Therapeutics

2025-07-3143:52

EP 197: From biobanks to breakthroughs: Linking genomics to drug discovery with Heiko Runz of insitro

EP 197: From biobanks to breakthroughs: Linking genomics to drug discovery with Heiko Runz of insitro

2025-07-2439:41

EP 196: A new vision for sequencing: In-sample multiomics and precision medicine with Molly He

EP 196: A new vision for sequencing: In-sample multiomics and precision medicine with Molly He

2025-07-1747:02

EP 195: From junk to therapy: The untapped power of regulatory RNAs with David Bumcrot of CAMP4 Therapeutics

EP 195: From junk to therapy: The untapped power of regulatory RNAs with David Bumcrot of CAMP4 Therapeutics

2025-07-1041:32

EP 194: Ontologies, diagnostics, and genomics for all with Melissa Haendel of UNC Chapel Hill

EP 194: Ontologies, diagnostics, and genomics for all with Melissa Haendel of UNC Chapel Hill

2025-07-0342:51

EP 193: Targeting autophagy to treat neurodegeneration with Frank Gentile of Casma Therapeutics

EP 193: Targeting autophagy to treat neurodegeneration with Frank Gentile of Casma Therapeutics

2025-06-2638:42

EP 192: From $88 to breakthroughs: Innovation in retinal gene therapy with Dr. Huma Qamar of Ocugen

EP 192: From $88 to breakthroughs: Innovation in retinal gene therapy with Dr. Huma Qamar of Ocugen

2025-06-1934:59

EP 191: Uncovering hidden histories and health insights from the Mexican Biobank with Andres Moreno-Estrada of LANGEBIO

EP 191: Uncovering hidden histories and health insights from the Mexican Biobank with Andres Moreno-Estrada of LANGEBIO

2025-06-1241:52

EP 190: Targeting regeneration to tackle Duchenne Muscular Dystrophy with Frank Gleeson of Satellos

EP 190: Targeting regeneration to tackle Duchenne Muscular Dystrophy with Frank Gleeson of Satellos

2025-06-0548:50

EP 189: From genetic heritability in twins to gut health with Tim Spector of King’s College London and Zoe

EP 189: From genetic heritability in twins to gut health with Tim Spector of King’s College London and Zoe

2025-05-2947:56

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

EP 166: Developing targeted therapies for ALS with Eric Green from Trace Neuroscience, Maze Therapeutics, and Stanford University

EP 166: Developing targeted therapies for ALS with Eric Green from Trace Neuroscience, Maze Therapeutics, and Stanford University

Sano Genetics